Dmitriy Krasnozhon

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

John R. Mackey, Manuel Ramos-Vázquez, Oleg Lipatov et al. · Journal of Clinical Oncology · 2014 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy

Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon et al. · Annals of Oncology · 2015 · 81 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer.

Michaela J. Higgins, Catherine Doyle, Stefan Paepke et al. · Journal of Clinical Oncology · 2014 · 34 citations

Medicine, Oncology, Pharmacology +17

Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment.

Young‐Hyuck Im, Petro Odarchenko, Daniela Grecea et al. · Journal of Clinical Oncology · 2013 · 33 citations

Medicine, Oncology, Pharmacology +17